According to data in the literature, the markers that can predict TIC in the BC HER2-positive population can be divided into [15,16,17,18,19,20]: biochemical: brain natriuretic peptide (BNP), N-terminal brain natriuretic peptide (NT-proBNP), troponins, myoglobin, creatine kinase-MB (CK-MB), glucose, uric acid, and lipids; morphological: decreased pre-treatment left ventricular ejection fraction (LVEF); clinical: history of hypertension, history of diabetes, radiotherapy treatment, older age, obesity (and overweight), race; genetic: HER2 polymorphism. This evidence concerns the gene NPPB and breast cancer.